AstraZeneca Pharma India Ltd. — Interim / Quarterly Report 2022

Nov 9, 2021

AstraZeneca4

==> picture [80 x 67] intentionally omitted <==

==> picture [79 x 7] intentionally omitted <==

----- Start of picture text -----

Bringln-g science t, paUe.n1$ .since 197!t
----- End of picture text -----

November 9, 2021

The Manager - Listing

BSE Limited,

1[st ] Floor, New Trading Ring Rotunda Building, P J Towers, Dalal Street, Fort, Mumbai 40000 l

• The Manager Listing

National Stock Exchange of India Ltd. Exchange plaza, 5[th ] Floor, PlotNo.C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai 400051

Dear Sir(s),

Sub: Outcome of the Board Meeting held on Tuesday November 9, 2021

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

At the Board meeting of the Company held on Tuesday, November 9, 2021 the Board of Directors considered and approved the Unaudited Financial Results of the Company for the quarter ended September 30, 2021. The said Unaudited Financial Results together with the Limited Review report of the Statutory Auditors dated November 9, 2021 are enclosed herewith.

Please take the same on record.

Thanking you,

For AstraZeneca Pharma India �µJV' Rudra Company Secretary & Legal C -� �ai.,

CORPORATE & REGO. OFFICE AstraZeneca Pharma India Ltd. P. B. No. 4525, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore - 560 045, INDIA

TEL : +91 ao 6774 8000 FAX : +91 80 6774 8857 CIN : L24231KA1979PLC003563

FACTORY TEL : +91 80 6774 9000 12th Mile on Bellary Road Venkatala, Kattigenahalli Village Yelahanka FAX : +91 80 2846 2208 .Bangalore - 560 063 +91 80 677 4 9628 INDIA

WEB : www.astrazeneca.com/india

A-,1Nlhrt il � Jndi:t lindled

Regd. Office: Bh)ir;k N1.1ffll Ftoor, �yata Embassi, Business Park. Racllenahalli, OulltrRing Road, Banplaf'II 5'0845 Statement or unaudiled nnanci.1I results forth11 qual'lllr and sitit R'IOflths ,mdiid JO S.phmber ZO?'I

	A-,1N i � Jdi lned Red. Ofice: Bhk N1.1f Ftor, �yta Embassi Business Park. Raclenahalli, OulrRng Roa, Banplf 50 Sttnt o unaudie nnanci.I result forth1 qualr and si Rths ,di J Sphr ZI
SI.N 1 2 3 • s • 7 e • 10 11 12 11
	o. Pfrulir lbveu■ a) Rwemse lnm aparalona b) Olcoml Totlinc "' (a) CoI a materials tcsfd ()Pwdohl.ad-itad (c) Chl lge: inveotalln cf fnWted goods, wtk-i-prcgru, and slock-in-d� (d Employn b. 1�t tit!l�• (e) l,1cat« �e (I A one1 IOTupected cel 0' {ne) •(g) Slrng. m,1lr �nd dullrt e�ln$« (h) Oe l?!nS (l)Fnanctco. Totl up,. Prob&oeptioal<"d�•ttrina,�and we 11-l) Eu:lp�ooal llem; Prt bifrettin.rrt ad t (344) .dilrilm Prt bore t (561 TeJ1pn, -Cooenttx -o�rerTtu To t epse Proft af r t 17 .. ) Ot«epnl h, irco(loHI A ltm l�t w nvl I- rtd lad t pro(t « fan, R..menu1ment gimOiH) o pst 1mlrmMt b1neftoQt lnim, ! 11ftct on abon Tol Dlar cmpnsin Tnc (lssJ, net af inco tu TNII mpre,IQ In fa l• pr f,101 Fi-p aui�h■f c=piUJ (Faev"I• of� '•Pf lqult shal) RH!K {exqudng realuato taffie n p balance shf) Eni91 pr ■li sna,offs J-uc. {bi and ditut)

==> picture [90 x 133] intentionally omitted <==

==> picture [100 x 56] intentionally omitted <==

AstraZeneca Pharma India Limited Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045

Statement of unaudited financial results for the quarter and sill months ended 30 September 2021

Notes:

• The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounling practices and policies to the extent applicable.

• 2 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with !he requirements of Ind AS 10B, 'Operating Segments'. Accordingly no segment information has been provided.

• 3 During the June 2021 quarter, the Company received a demand notice for an amount of Rs. 15,738.85 lakhs (and interest thereupon) U11der Trade Margin Rationalisation notification ("TMR notification") from National Pharmaceutical Pricing Authority (NPPA) alleging overcharging of a patented anti-cancer drug sold during the period of 8 March 2019 to 31 Januaiy 2021. The said drug has been included with certain other anti-cancer medicines, on which trade margin caps are applicable under TMR notification.

• Based on evaluation, Management is of the view that TMR notification is not applicable to the aforesaid patented drug and all applicable laws relating to the pricing of the product have been complied with. The Company has flied a Writ Petition before the High Court of Delhi challenging the NPPA's demand notice and the matter Is pending adjudication. Based on assessment, supported by external legal advice, Management has concluded that it has a strong case and the Company can defend its position. Accordingly, no provision has been made in these financial results.

• 4 Previous period's figures have been regrouped/reclassified, where necessary, lo conform with the current period's presentation for the purpose of comparability.

• 5 This statement of finanacial results was reviewed and recommended by the Audit Commil!ee of the Board and subsequenUy approved by the Board of Directors at their respective meetings held on 09 November 2021. The StaMory auditors of the Company have earned out a limited review of this statement of financial results for the quarter ended 30 September 2021.

By er of the Board of Directors Fo traZeneca Phanna India Limited r"'

Place: Bengaluru Data: 09 November, 2021

==> picture [100 x 59] intentionally omitted <==

AstraZeneca Pharma India Limited Regd Office : Block N1, 12th Floor, Manyata Embassy Bueiness Park, Rachenahalli, Outer Ring Road, Bangalore 560 045

Unaudited Statement of a&1ets and llabilitles

==> picture [404 x 502] intentionally omitted <==

----- Start of picture text -----

fRs in lakhS)
SI.No. Balance Sheet Asal Asat
3D September 2021 31 March 2.021
Unaudid Audited
ASSETS
1 Non-current assets
(a) Property, plant and equipment 6,632.22 6,990.88
(b) Right-of-use assets 923.36 1,105.37
{cl Capital work-in-progress 618.36 402.17
(dl Financial assets
(I) Loans 36.05 42.52
(ii) Other financial assets 321.75 390.25
(e) Current tax assets 5,431.89 5,010.17
(f) Defer ed tax assets 1,606.49 1,452.94
(g) Other non-current assets 294.23 201.35
Sub-total - Non-current assets 15,864.37 15,595.65
2 Current assets
(a) Inventories 15,868.47 15,979.91
(b) Financial assets
(i) Trade receivables 8,213.56 8,518.60
(ii [) ] Cash and cash equivalents 39,682.68 35,233.81
(iii) Bank balances other than cash and cash equivalents 1.82 1.50
(iv) Loans 26.71 26.53
(v) Other financial assets 588.70 574.79
(c) Other current assets 1.160.63 1,50.35
Sub-total • Current assets 65,542.57 61,875.49
TOTAL. ASSETS 81406.94 77 471.14
1 EQUITY AND LIABILITIES
Equity
(a) Equity share capital 500.00 500.00
(bl Other equity 46,789.43 45,117.28
Sub-total-Shareholdell5' funds 47,289.43 45,617.28
LIABILITIES
Non-current llabllltles
(a) Financial LiabUities
(i) Lease liabilities 670.89 862.77
(b) Provisions 540.13 641.13
Sub-total • Non-current liabilities 1,211.02 1,503.90
2 Current liabilities
(a) Financial Liabilities
(I) Trade payables
Total outstandin [g ] dues of micro enterprises and small 119.72 29.58
ente [rp] rises
Total outstandinenterprises and small ente [g ] dues of creditors other than micro [rp] rises 19,704.64 17,807.01
(ii) Lease liabilities 372,71 350.68
(fi ) Other financial liabilities 4,994.94 5,259.11
(b) Other current liabilities 3,507.25 2,647.95
(c [) ] Provisions 3,997.23 3,692.32
(d) Current la>< liability 210.00 53.31
Sub-total - Current liabilities 32,96.49 30,349.96
TOTAL· EQUITY AND LIABILITIES 81406.94 77471.14
----- End of picture text -----

Note: Balances of certain assets as at March 31, 2021 have been re[g] rou[ped] / reclassified, where necessa[ry] , to com[p] l[� ] with the amended Division 11 of Schedule 111.

==> picture [72 x 107] intentionally omitted <==

==> picture [99 x 56] intentionally omitted <==

AstraZeneca Phanna India Limi!Bd

Regd Office: Block N1, 12th Floor, Manyata Embas y Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045 Unaudited Statement of Cash Flows for six months ended 30 September 2021

	(Rs In lakhsl	(Rs In lakhsl
Particulars	Six months ended 30 September 2021	Six months ended 30 September 2020
	Unaudited 2,974.11 903.65 (31.33) (541.77) - 92.20 10.88 209.51 51.28	Unaudited 6,195.43 91836 (105.92) (475.79) (153 20) 76 00 11.21 169.06 55.07
A) Cash flow from operating activities Prft befor tax Non-csh adjustments for Deprciation and impairment expense (Proft) on sale of proper, plant and equipment (net) Interst income on deposits crried at amorised cost Intert incme on Incme tax rfnd Employee sto cmpensation exP9nse Unralised freign exchange gain (net Allowanc fr expete credit los (net) Financ cst Operating profit before working capital changes Changes in wor ng cpitl: (Increase)_I_Derease in trade recivabls (Increase) / Decrase in Inventries (Increase) / Decr in loans (Incase)_I_Derease in oter fnancial aset (Incas)_I_Derese in oter assets Increase/ (Deree) in trade payables I Incrase/ (Derase) in provisions Inceas/ (Derase) in other �nancial liabililies Incase/ (Derease) in other liab ltles Cash generated from operons Incm taxes pai (net of refund) Net cash genel frm operatng activities (A) Bl Csh flows from investing activities Interst incme on bank depsits Pr fm maturit of bank depsits Purhas of propert, plant and euipment, including cpital worijn.proress Proc s frm sle of property, plant and euipment Net cash generated frmI(used Jn) investing activities (B) C) Cash flows from financing activities Prncipal payment of lese liabilities Inters cst on leas liabiliies Dividend pid Net cash generatd fom/ (used in) financing actvities (C) D) Net increase (dcrease) in csh and cash equivalent {A+B+C) E) Cash and cash equivalent at te beginning of the period \ F) Cash and cash equivalent at the end of the period (O+E)
	3.668.53 84.80 111.43 6.28 67.49 301.31 1,987.62 145.28 (41138) 859,03	6,690.22 176.01 (2,905.78) (0 58) (4.37) 622.30 (3,323.10) 483.86 (238.04) 54,54
	6 820.39	1,555.06
	(1,668.90)	{1,421.96)
	5.151.49 528.87 - (552.82) 42.45	133.10 605.56 14.699.99 (247.00) 110 48
	18.50 (169.8) (51.28) (500,00) j721.12)	15.169.03 (132.01) (55.07) (500 00) (687.08)
	4,448.87 35,233.11	14,615.05 8,350.12
	39.682.68	22.965.17

==> picture [77 x 122] intentionally omitted <==

==> picture [98 x 56] intentionally omitted <==

Price Waterhouse & Co Chartered Accountants LLP

To The Board of Directors AstraZeneca Pharma India Limited Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bengaluru - 560 045

1. We have reviewed the unaudited financial results of AstraZeneca Pharma India Limited (the "Company") for the quarter and the half year ended September 30, 2021 the year to date results for the period April 01, 2021 to September 30, 2021 which are included in the accompanying "Statement of unaudited financial results for the quarter and six months ended 30 September 2021", "Unaudited Statement of assets and liabilities as at 30 September 2021" and "Unaudited statement of cash flows for the six months ended 30 September 2021" (together referred to as the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes.

2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

4. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse & Co Chartered Accountants LLP Firm Registration Number: 304026E/ E-300009 Prasanna Padar Mahabala 1?50['a11/'\ ][o] Partner Place: Bengaluru Membership Number: 206477 Date: November 09, 2021 UDIN: 21206477A DE6739 : .......................................... .......................................................... , .................................................................................. , ............................. . Price Waterhouse & Co Chartered Accountants LLP, 5th Floor, Tower 'D', The Millenia, 1 & 2 Murphy Road Ulsoor, Bangalore-560 008 T:+91 (Bo) 4079 5000, F:+91 (Bo) 4079 5222

Registered office and Head office: Plot No. Y-14, Block EP, Sector v. Sall Lake Electronic Complex, Bidhan Nagar, Kolkata 700 091

Price Watemouse & Co, (a Partnership Firm) converted into Price Waterhouse & Co Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-4362) with effect from July 7, 2014. Post its conversion lo Price Waterhouse & Co Chartered Accountants LLP, its /CAI registration number is 304026E/E-300009 (/CAI registration number before conversion was 304026E)